Provectus Biopharmaceuticals, Inc.
PVCTOTCCIK 315545HealthcareFiscal year ends Dec 31
Reports and events: 385 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1313:21 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001493152-26-037671 |
| 2026-07-2215:04 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001493152-26-034217 |
| 2026-07-0119:37 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001493152-26-031379 |
| 2026-06-2209:00 ET | 8-K | 5.07 Shareholder vote results | 0001493152-26-029512 |
| 2026-06-1814:59 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-029280 |
| 2026-05-1413:52 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001493152-26-022950 |
| 2026-04-3011:06 ET | DEF 14A | Proxy statementPeriod 2026-04-30 | 0001493152-26-019805 |
| 2026-04-2121:19 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-018160 |
| 2026-03-2617:38 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001493152-26-012726 |
| 2026-02-0215:30 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-004730 |
| 2025-12-0809:53 ET | SCHEDULE 13D | Ownership report, active investor | 0001493152-25-026550 |
| 2025-12-0121:52 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001493152-25-025639 |
| 2025-11-1314:36 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001493152-25-022229 |
| 2025-08-1413:56 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001641172-25-023864 |
| 2025-06-2006:15 ET | 8-K | 5.07 Shareholder vote results | 0001641172-25-015695 |
| 2025-06-1808:43 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001641172-25-015520 |
| 2025-05-1614:24 ET | 10-K/A | Annual report, amendedPeriod 2024-12-31 | 0001641172-25-011210 |
| 2025-05-1416:14 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001641172-25-010273 |
| 2025-05-0118:43 ET | DEF 14A | Proxy statementPeriod 2025-04-30 | 0001641172-25-007928 |
| 2025-04-1613:35 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001641172-25-004995 |
| 2025-03-2817:38 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001641172-25-000993 |
| 2025-01-2213:31 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-003193 |
| 2024-12-2609:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-24-052029 |
| 2024-12-1109:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-049571 |
| 2024-12-0619:45 ET | SC 13D/A | Ownership report, active investor, amended | 0001493152-24-049162 |
| 2024-12-0519:57 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-24-048734 |
| 2024-11-1408:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-045353 |
| 2024-11-1215:34 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001493152-24-044720 |
| 2024-08-1915:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001493152-24-033053 |
| 2024-08-1313:21 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001493152-24-031524 |
| 2024-07-1715:50 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-24-028157 |
| 2024-07-0319:29 ET | SC 13D | Ownership report, active investor | 0001493152-24-026262 |
| 2024-06-2515:41 ET | 8-K | 1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-24-025080 |
| 2024-06-2113:56 ET | 8-K | 5.07 Shareholder vote results | 0001493152-24-024661 |
| 2024-06-2009:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-024449 |
| 2024-05-1414:43 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001493152-24-019184 |
| 2024-05-0613:56 ET | DEF 14A | Proxy statementPeriod 2024-05-06 | 0001493152-24-017882 |
| 2024-04-2913:10 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0001493152-24-016883 |
| 2024-04-1616:58 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-014848 |
| 2024-03-2814:35 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001493152-24-011699 |
| 2024-03-2712:10 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-011443 |
| 2024-03-2616:48 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-24-011327 |
| 2024-02-2209:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-007506 |
| 2024-02-1508:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-006815 |
| 2023-11-1411:35 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001493152-23-040856 |
| 2023-08-1413:40 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001493152-23-028230 |
| 2023-06-2214:33 ET | 8-K | 5.07 Shareholder vote results | 0001493152-23-022116 |
| 2023-06-2109:50 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-23-021927 |
| 2023-05-1114:41 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001493152-23-016356 |
| 2023-05-0113:58 ET | DEF 14A | Proxy statementPeriod 2023-05-01 | 0001493152-23-014910 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 11:33 ET. Listed shows no prices and gives no investment advice.